Wednesday, 22 May 2019

You are here

Does RA kill you? Let me count the ways….and what you can do about it

There were many presentations at EULAR 2018 in Amsterdam about the mortality of RA.

Excess mortality seems to start after 6 years of RA with an excess of approximately 13 to 14% over 10 years (0P0344). This was observed in two large administrative (billing) databases from the provinces of Ontario (27,405 people with RA) and British Columbia (13,834 with RA), Canada and showed the same results matched to age and sex matched general population. Others have found that most deaths are from cardiovascular events and then cancer and less often infection (but more common than the general population). The Oslo RA register showed that over time the excessive mortality gap in RA is decreasing (FRI0043) where 10 year mortality was less in the patients studied (from 2004-2008) vs from 1994-1998 and 1999-2003.

So it is interesting that plaquenil (HCQ) prolongs survival (OP091). Incident RA pts from Denmark from 2004-14 compared users of HCQ to matched non-users. The author stated that mostly HCQ is prescribed in combination with MTX and not as monotherapy but the proportion with HCQ monotherapy was not provided so there could be imbalance (confounding) where perhaps HCQ users had less severe disease if many had monotherapy. The all-cause mortality was 17% reduced and CV deaths decreased by 22%. Interestingly there was no reduction in diabetes which other studies have shown.

Mortality was increased in seropositive RA patients (ACPA and/or RF) in an administrative database (HUMANA) that was linked with a lab database. Interestingly mortality was less if using bDMARDs compared to csDMARDs (OP0195). Even more interesting, MTX with a bDMARDs had less cardiovascular events than use of a bDMARD alone (from Medicare database) (OP0192).  

So, what should we do? I don’t know the full answer but will continue to use HCQ (as I often start ERA pts on triple therapy) and may consider less likely to stop it and when using a bDMARD I have reasons beyond better disease control and retention to try to encourage concomitant MTX use if tolerated. Finally, we can’t forget about the identification and treatment of modifiable CV risk factors in our patients!

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Opioids, SSRIs and Steroids Increase Fracture Risk in RA

Analysis of a large US observational rheumatoid arthritis (RA) patients finds that opioids, SSRIs and glucocorticoids were associated with increased risk of fracture in RA, whereas statins and TNFi had a decreased vertebral fracture risk.

Denosumab Protects Against RA Erosions

Combining denosumab (Prolia) with a conventional disease-modifying antirheumatic drug (DMARD) such as methotrexate showed promise for slowing radiographic damage in rheumatoid arthritis (RA), a manufacturer-sponsored phase III trial called DESIRABLE found.

New ACR/AF Guidelines on JIA Polyarthritis and Uveitis

The American College of Rheumatology (ACR) and the Arthritis Foundation (AF) have released two guidelines on management of juvenile idiopathic arthritis (JIA). The first addresses the treatement of non-systemic polyarthritis, sacroilitis and enthesitis; and the second focuses on JIA associated uveitis - screening, monitoring and treatment.

Shorter Treatment Succeeds in Septic Arthritis

Two weeks of antibiotic therapy was as effective as 4 weeks for septic arthritis, a prospective single-center study found.

Among 77 patients randomized to a 4-week course of therapy following surgical drainage for native joint bacterial arthritis, the rate of complete microbiological remission after at least 2 months of follow-up was 97%, according to Ilker Uçkay, MD, of Uniklinik Balgrist in Zurich, Switzerland, and colleagues.

Targeting GM-CSF Works in Rheumatoid Arthritis

Namilumab, a monoclonal antibody that targets the granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand, showed promise as a treatment for rheumatoid arthritis (RA) in a phase II study.